Streptococcus pneumoniae ( pneumococcus) is a common cause of pneumonia and meningitis worldwide. Since 2000, a pneumococcal conjugate vaccine including 7 of more than 93 known serotypes (PCV7) has reduced IPD directly among the target population of children aged <5 years and indirectly among those not vaccinated [1] through reductions in nasopharyngeal colonization and transmission from vaccinated children [2] . Nonetheless, in the United States, nearly 40 000 cases of invasive pneumococcal disease (IPD) resulting in 4000 deaths still occurred among adults in 2010 [3] .
Individuals with certain high-risk illnesses [4] accounted for >50% of IPD cases in the United States before PCV7 introduction [5] , and that proportion increased after PCV7 introduction [6] . Although studies have shown an overall decline in IPD incidence among adults since PCV7 introduction in children [5] , the indirect benefits of PCV7 for adults with highrisk conditions is not known and may be different compared with adults without those conditions. Efficacy of the 23-valent polysaccharide vaccine (PPV23), recommended for certain adult populations by the Advisory Committee on Immunization Practices (ACIP), is likely to be lower among persons with comorbid conditions compared with healthier adults [7] .
To inform prevention policies for adults, we evaluated the epidemiology of certain high-risk illnesses among adults with IPD. We compared the change in incidence of IPD among adults with and without high-risk conditions by race, age, and serotype and determined which vaccine serotypes caused disease among adults with and without high-risk conditions.
METHODS
We used Active Bacterial Core surveillance (ABCs), part of the Centers for Disease Control and Prevention's (CDC) Emerging Infections Program, to gather pneumococcal case data. ABCs is an active, population-and laboratory-based surveillance program that has monitored IPD and other bacterial infections in the United States since 1995. The analysis included any area participating in ABCs during 1998-2009. In 2009, approximately 22 million persons aged ≥18 were under surveillance. Cases of IPD were defined by the isolation of S. pneumoniae from a normally sterile body fluid in a resident of the surveillance area. To ensure complete case identification, surveillance personnel routinely contacted all participating microbiology laboratories and conducted periodic audits of their records. ABCs uses a standardized case report form to gather information on demographics, clinical presentation, high-risk conditions, and outcome of disease for each case (www.cdc. gov/abcs/methodology/data-collect-forms.html). High-risk conditions queried by ABCs (Table 1) include those listed as indications for the PPV23 by ACIP [8] . A high-risk condition was marked as "yes" on the ABCs case report form if it was noted to be present in the patient's medical record at the time when treatment for IPD was administered. If no high-risk conditions were noted in the medical record, none were considered to be present. Owing to local statutes, HIV/AIDS status was not gathered in New York.
Serotyping was performed at the CDC and the Minnesota Department of Health reference laboratories using the Quellung reaction in the presence of serotype-specific antisera.
Cases were grouped by pneumococcal vaccine serotype as PCV7 serotypes (4, 6A, 6B, 9V, 14, 18C, 19F, 23F), PPV23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,  17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), and 13-valent pneumococcal conjugate vaccine (PCV13) serotypes (1, 3, 4, 5, 6A,  6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) . Serotype 6A was included among the PCV7 serotypes owing to the cross-protection provided by the serotype 6B antigen [9] . PCV13 replaced PCV7 in the infant immunization schedule in February 2010. Cases of IPD caused by serotypes other than serotype 6A and those included in PCV7 were classified as non-PCV7 serotypes.
We included cases of IPD that occurred during 1998-2009 among adults ≥18 years old. We stratified cases into ages 18-49 years, 50-64 years, and ≥65 years. Race groups included white, black, and other. Cases were assigned "other" race group if race was designated as American Indian, Alaska Native, or Asian/Pacific Islander. We included cases of unknown race in our incidence rate calculations; cases with unknown race were assigned race on the basis of the race distribution of cases with known race within age groups and Because the US Census does not collect specific information about the prevalence of high-risk conditions in the population, we used the National Health Interview Survey (NHIS) to estimate the number of persons in the United States living with certain illnesses. The NHIS addresses multiple health-related conditions among noninstitutionalized civilian adults and has been conducted annually since 1957 by the National Center for Health Statistics (http://www.cdc.gov/nchs/nhis/about_nhis. htm). NHIS uses a multistage probability design with sample weights provided to account for the complex sampling design, including unequal probabilities of selection, nonresponse, and planned oversampling of certain subgroups. Thus, the data provide an estimated number of persons with and without specific underlying illnesses in the United States. We considered illnesses that were indications for PPV23 [8] and that were captured by both ABCs and NHIS during 1998-2009. These illnesses included diabetes, cancer, chronic pulmonary disease, chronic cardiovascular disease, renal disease, HIV/AIDS, liver disease, and alcohol abuse (Table 1) . Using these medical conditions, we defined 2 mutually exclusive groups: those with and without evidence of ACIP indications for PPV23.
ABCs and NHIS data were combined to calculate overall and serotype-, race-and age-specific incidence rates among persons with and without ACIP indications. We assessed changes in incidence over time during 1998-2009 and compared 2009 rates with average rates for 1998-1999, the baseline period just before PCV7 introduction. To evaluate which vaccines might provide the most protection to those with and without ACIP conditions, we compared the distributions of serotypes causing IPD in these 2 groups.
Data analyses were performed using SAS software, version 9.2 (SAS Institute) and SUDAAN software (RTI International). Standard error estimates from the NHIS were used to calculate the 95% confidence intervals (CIs) for the incidence rates. Percentage change in incidence between time periods was determined using relative risks ( percentage change = [relative risk -1] × 100). Proportions were compared using the χ 2 test. P values and associated 95% CIs were also calculated. P < .05 was considered statistically significant. If 95% CIs for percentage changes did not overlap, differences were considered statistically significant. ABCs case reporting and isolate collection were considered to be surveillance activities and were exempt from CDC institutional review. The surveillance protocol was also evaluated by each participating surveillance site, and either the protocol was deemed exempt from review or appropriate institutional review board approval was obtained. Informed consent was not required by CDC or individual site institutional review boards.
RESULTS
During 1998-2009, we identified 35 925 cases of IPD among noninstitutionalized adults in the ABCs sites. There were 5699 and 3338 cases reported, respectively, during 1998-1999 (the pre-PCV7 period) and 2009. During 1998-1999, 51% of cases had an ACIP indication for PPV23; by 2009, this proportion had increased to 61% (P < .0001; Table 2 ). On average, 88% of cases had isolates available for serotyping each year. 
Comorbid Illnesses Among Observed Cases and the General Population
Although comorbid illnesses identified among observed IPD cases varied by age group, diabetes was the only condition frequently observed among all 3. In 2009, HIV/AIDS, alcoholism, and diabetes were the most commonly reported conditions, occurring among 36%, 30%, and 23%, respectively, of all IPD cases aged 18-49 years with ACIP indications for PPV23. Among cases aged 50-64 years with ACIP indications, diabetes (35%), chronic obstructive pulmonary disease (COPD; 33%), and cancer (20%) were most frequent. Finally, among persons aged ≥65 years with ACIP indications, cardiac disease (50%), COPD (42%), and diabetes (35%) were the most common conditions. Among IPD cases, the frequency of certain ACIP indications for PPV23 varied by race (Table 3) . For example, persons of white race were more likely than those of black race to have chronic lung disease (24% vs 12%) and cardiac disease (22% vs 14%). Conversely, HIV/AIDS was identified among more IPD cases of black race (27%) than cases of white race (2%), and half of the reports of HIV/AIDS associated with IPD (119/239, 50%) occurred among black persons aged 18-49 years, whereas black persons comprised only 31% of all cases in this age group (Table 3) . This association explains, at least in part, the higher incidence of IPD among black persons aged 18-49 years with PPV23 indications compared with other groups. Our analysis of 2009 NHIS data also indicated that, among noninstitutionalized, civilian adults aged 18-49 years, diabetes was among the most frequently identified ACIP indications for PPV23. The prevalences of diabetes, chronic lung disease, and alcohol abuse-all ACIP indications for PPV23-were similar among adults aged 18-49 years (3.8%, 3.5%, and 2.7%, respectively), but the prevalence of diabetes was substantially higher (diabetes 14.1%, cancer 10.5%, cardiovascular disease 8.6%) among adults aged 50-64 years. Diabetes was the third most prevalent ACIP indication for PPV23, apart from age itself, among adults aged ≥65 years (cancer, 24.5%; cardiovascular disease, 20.6%; diabetes, 19.5%).
Overall Trends in IPD Incidence
Between 1998-1999 (the pre-PCV7 period) and 2009, the cumulative incidence of IPD for all serotypes declined significantly among nearly all adult age groups, regardless of race or presence of ACIP indications for PPV23 (Figure 1 ; Table 4 ). IPD incidence for all serotypes remained higher in 2009 among those with an indication for PPV23 compared with those with no indication for PPV23, in part because absolute increases in non-PCV7-type IPD tended to be greater among adults with ACIP indications compared with adults without ACIP indications.
Although rates among blacks remain higher than rates among whites within each of the age and ACIP indication groups, there were significant decreases in the incidence of all serotype IPD within each race group (Table 4) . During 1998-1999, there were instances where rates among blacks with no ACIP indication were as high or higher than rates among whites with any ACIP indication. In 2009, after PCV7 introduction, these differences either diminished or reversed. For example, among those aged 18-49 years, the rate among blacks with no ACIP indication decreased from 24.7 to 8.8 per 100 000, compared with whites with ACIP indications among whom the rate declined from 24.7 per 100 000 in 1998-1999 to 13.8 per 100 000 in 2009.
Serotype-Specific IPD Rates
We observed statistically significant declines in the incidence of PCV7-serotype IPD within each age, race, and ACIP indication group (Table 4) . PCV7-serotype rates declined >80% within each stratum. PCV7-serotype declines were most substantial among blacks aged 18-49 years with no ACIP condition (97% [95% CI, 96%-98%]), whereas whites aged 50-64 years with an ACIP condition experienced the smallest declines (82% [95% CI, 80%-83%]). In most age strata, rates of non-PCV7-serotype disease increased significantly, but not enough to outweigh declines in PCV7-serotype IPD. A notable exception to this observation occurred among whites aged 50-64 years with no ACIP indication; this group experienced the greatest relative increase in non-PCV7-serotype disease during 1998-2009 (133% [95% CI, 120%-146%]), although the absolute increase in non-PCV7-type IPD (6.2 cases per 100 000) was less than that for certain other groups (Table 4) . Four groups had declines in rates of non-PCV7 serotype IPD: blacks aged 18-49 years with and without ACIP indications, blacks aged 50-64 years with no ACIP indication, and blacks aged ≥65 years with no ACIP indication. These reductions were largely related to disproportionate increases in the size of those populations relative to changes in numbers of cases of non-PCV7 serotype IPD. For example, during 1998-2009, the population of adults aged 50-64 years without PPV23 indications increased by 53% whereas the total number of cases of IPD in this age group increased by only 27 percent.
Cases of IPD Potentially Preventable by Currently Available Vaccines
Depending on age and the presence of ACIP indications for PPV23, 60%-76% of IPD cases occurring in 2009 were caused by PPV23 serotypes, whereas 39%-55% of IPD cases were caused by PCV13 serotypes (Table 5) .
DISCUSSION
We evaluated interactions among high-risk conditions, race, and age as they relate to trends in IPD incidence among adults following introduction of PCV7 for children. Although differences in rates of IPD among these different groups remain, we observed striking reductions in PCV7-type IPD in all groups, which supports the hypothesis that PCV7 use among children has profoundly reduced pneumococcal transmission [1, 5, 11] . At the same time, adults with high-risk conditions continue to be disproportionately affected by IPD caused by non-PCV7 serotypes [4, 6, 12] , independent of age and race, and they account for a larger proportion of cases in 2009 compared with the years before PCV7 introduction.
Our observation that diabetes was prevalent among IPD cases of all race and age groups is important for several reasons. First, diabetes among US adults has reached epidemic levels. Recent estimates suggest that the number of persons living with diabetes will triple between 2005 and 2050, to nearly 50 million individuals [13] . Second, diabetes is a risk factor for chronic renal failure, which is itself an independent risk factor for IPD [14, 15] . In this way, the diabetes epidemic could "multiply" the risk for IPD over the coming decades. Third, diabetes helps to explain the increased incidence of IPD among blacks vs whites, and is especially concerning given that the prevalence of diabetes appears to be increasing faster among blacks than whites [16] . Finally, little is known about the immune defects that lead to increased risk for pneumococcal disease among persons with diabetes.
Numerous studies have documented that blacks have substantially higher rates of IPD compared with whites [4, 17, 18] . The reasons for this difference are multifactorial. Like diabetes, HIV infection was more prevalent among black compared with white individuals with IPD. High IPD rates among blacks with HIV/AIDS have been well documented [19] and HIV-infected adults are more likely to be carriers of pneumococcus [20] . Previous studies have shown that, even after controlling for underlying conditions, socioeconomic factors, such as poverty, explain a substantial portion of the racial disparity in pneumococcal disease [21] .
PCV13 was licensed for use among children in the United States in February 2010, and adults may benefit from this new vaccine through herd effects. PCV13 was licensed for adults aged ≥50 years old in December 2011 [22] . In June 2012, ACIP recommended that all adults with immunocompromising conditions receive a single dose of PCV13, in addition to previously recommended doses of PPV23 [23] . For all other adults, PPV23 remains the only recommended vaccine for prevention of pneumococcal disease pending the results of a randomized controlled trial in the Netherlands [24] and data on the indirect effects of using PCV13 in children [22] . Rates of IPD remain high among persons for whom PPV23 is recommended, in part because of low coverage with this vaccine (especially among persons with underlying conditions [3, 25] ), its limited effectiveness in persons with high-risk conditions, and the potentially short duration of protection [26] . Our analysis has limitations. Some ABCs pneumococcal surveillance sites did not begin to collect underlying illness data until after the start of our analysis period. As a result, some persons noted to have no indication for PPV23 may have had a high-risk condition and rates for high-risk adults may be underestimated. ABCs and NHIS differ in their collection of underlying illness data and numerators and denominators may not match exactly for some conditions. This is especially evident in the reductions in non-PCV7-type IPD in some groups (eg, those aged 50-64 years without ACIP indications for PPV23). Because the denominators substantially increase for some groups, they would have the effect of biasing downward our estimate of rates for these same groups. Certain conditions (eg, diabetes) may be more likely to be captured in the inpatient medical record than others (eg, alcoholism) and are therefore more likely to be captured by ABCs. Some conditions known to be risk factors for IPD (eg, asplenia, sickle cell disease, cerebrospinal fluid leak, and cochlear implant) were not included because NHIS did not include questions regarding these conditions during the time period of our analysis. NHIS also excludes military personnel and incarcerated persons, 2 groups which are not explicitly identified by ABCs; therefore, we were unable to exclude them from the numerator in our rate estimates. We estimated incidence rates using ABCs population-based active surveillance data for numerators and nationally collected NHIS data on health status among adults for denominators. We do not know how well these estimates approximate the true rates of disease among these groups; however, we believe they do allow reasonable comparisons both over the analysis period and across the age, race, and illness groups evaluated.
While adults with any ACIP indication for PPV23 should continue to receive PPV23, our findings suggest that additional prevention approaches are needed. ACIP recently recommended use of PCV13, which includes serotypes causing about 50% of IPD cases, for adults with immunocompromising conditions [23] . Given the low PPV23 vaccination rates among persons aged <65 years, providers should seek opportunities to increase vaccination coverage in this group. In addition, use of PCV13 among children may confer similar herd immunity for adults as that experienced with PCV7.
Notes

